On the other hand, GLP-1 receptor agonists have been shown to reduce the risk of MACE, macrovascular endpoints such as stroke and myocardial infarction, and cardiovascular death in people with T2DM and established cardiovascular disease [137]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.